Donate

industry_news_banner

 

Novo Nordisk recently announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application for REBINYN® (Coagulation Factor IX (Recombinant), GlycoPEGylated) for the treatment of adults and children with hemophilia B. Novo Nordisk expects to launch REBINYN® in the U.S. in the first half of 2018.

For more info on REBINYN, read the full press release here.

Facebook Comments


Sign up for E-mails, Dateline Magazine, and other ways to stay connected.